Key Takeaways MMSI's $22M C2 CryoBalloon deal broadens GI portfolio, targeting Barrett's esophagus treatment growth.MMSI expects $6-$8M in 2026 revenues from C2 CryoBalloon, despite near-term EPS dilution through 2025-26.MMSI strengthens GI market presence with innovative ablation tech, enhancing long-term growth outlook.Merit Medical Systems (MMSI) announced that it has signed a definitive agreement to acquire the C2 CryoBalloon technology from Pentax of America, a subsidiary of PENTAX Medical, Inc. The in ...